Total Payments
$179,087
2024 Payments
$78,898
Companies
10
Transactions
172
Medicare Patients
1,691
Medicare Billing
$194,676
Payment Breakdown by Category
Consulting$108,157 (60.4%)
Other$36,130 (20.2%)
Research$16,835 (9.4%)
Travel$13,150 (7.3%)
Food & Beverage$4,705 (2.6%)
Education$110.00 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $108,157 | 36 | 60.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $31,840 | 13 | 17.8% |
| Unspecified | $16,835 | 3 | 9.4% |
| Travel and Lodging | $13,150 | 47 | 7.3% |
| Food and Beverage | $4,705 | 70 | 2.6% |
| Honoraria | $4,290 | 1 | 2.4% |
| Education | $110.00 | 2 | 0.1% |
Payments by Type
General
$162,252
169 transactions
Research
$16,835
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Alexion Pharmaceuticals, Inc. | $49,719 | 41 | $0 (2024) |
| UCB, Inc. | $41,539 | 36 | $0 (2024) |
| ARGENX US, INC. | $30,272 | 41 | $0 (2024) |
| UCB SA | $22,117 | 14 | $0 (2024) |
| Amgen Inc. | $15,597 | 16 | $0 (2024) |
| Janssen Global Services, LLC | $7,244 | 9 | $0 (2024) |
| CSL Behring | $5,177 | 8 | $0 (2019) |
| Janssen Scientific Affairs, LLC | $3,061 | 5 | $0 (2024) |
| Johnson & Johnson Health Care Systems Inc. | $2,725 | 1 | $0 (2024) |
| Janssen Biotech, Inc. | $1,635 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $78,898 | 70 | UCB, Inc. ($30,081) |
| 2023 | $54,299 | 41 | Alexion Pharmaceuticals, Inc. ($17,724) |
| 2022 | $32,018 | 39 | ARGENX US, INC. ($12,163) |
| 2021 | $5,968 | 4 | UCB, Inc. ($3,163) |
| 2020 | $1,020 | 1 | Alexion Pharmaceuticals, Inc. ($1,020) |
| 2019 | $6,884 | 17 | CSL Behring ($5,177) |
All Payment Transactions
172 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/29/2024 | ARGENX US, INC. | VYVGART (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,550.00 | General |
| Category: Immunology | ||||||
| 11/18/2024 | Janssen Global Services, LLC | — | Consulting Fee | Cash or cash equivalent | $2,180.00 | General |
| 11/06/2024 | Amgen Inc. | UPLIZNA (Biological) | Travel and Lodging | Cash or cash equivalent | $363.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/06/2024 | Amgen Inc. | UPLIZNA (Biological) | Travel and Lodging | Cash or cash equivalent | $38.16 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/01/2024 | Amgen Inc. | UPLIZNA (Biological) | Consulting Fee | Cash or cash equivalent | $3,850.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/25/2024 | Alexion Pharmaceuticals, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,720.00 | General |
| 10/25/2024 | Alexion Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $240.98 | General |
| 10/25/2024 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $132.21 | General |
| 10/25/2024 | Alexion Pharmaceuticals, Inc. | — | Travel and Lodging | Cash or cash equivalent | $47.93 | General |
| 10/25/2024 | Alexion Pharmaceuticals, Inc. | — | Travel and Lodging | Cash or cash equivalent | $47.66 | General |
| 10/24/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $112.25 | General |
| Category: Rare Disease | ||||||
| 10/18/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $118.54 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/14/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $19.56 | General |
| Category: Rare Disease | ||||||
| 09/05/2024 | UCB, Inc. | Rystiggo (Biological) | Consulting Fee | Cash or cash equivalent | $4,151.82 | General |
| Category: Neurology | ||||||
| 09/05/2024 | ARGENX US, INC. | VYVGART (Drug) | Consulting Fee | Cash or cash equivalent | $510.00 | General |
| Category: Immunology | ||||||
| 08/21/2024 | UCB, Inc. | — | Consulting Fee | Cash or cash equivalent | $7,680.00 | General |
| 08/21/2024 | Alexion Pharmaceuticals, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,540.00 | General |
| 08/21/2024 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $125.69 | General |
| 08/21/2024 | Alexion Pharmaceuticals, Inc. | — | Travel and Lodging | Cash or cash equivalent | $110.73 | General |
| 08/21/2024 | Alexion Pharmaceuticals, Inc. | — | Travel and Lodging | Cash or cash equivalent | $89.12 | General |
| 08/19/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | Cash or cash equivalent | $161.96 | General |
| Category: Inflammation/Rare Disease | ||||||
| 08/19/2024 | Amgen Inc. | UPLIZNA (Biological) | Travel and Lodging | Cash or cash equivalent | $98.28 | General |
| Category: Inflammation/Rare Disease | ||||||
| 07/25/2024 | UCB, Inc. | — | Consulting Fee | Cash or cash equivalent | $6,400.00 | General |
| 07/23/2024 | Amgen Inc. | UPLIZNA (Biological) | Consulting Fee | Cash or cash equivalent | $3,850.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 07/23/2024 | Amgen Inc. | UPLIZNA (Biological) | Consulting Fee | Cash or cash equivalent | $2,750.00 | General |
| Category: Inflammation/Rare Disease | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A MULTICENTER, OPEN-LABEL STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN ADULT SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS | UCB SA | $14,304 | 2 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, SECUKINUMAB-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN ADULT SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS. | UCB SA | $2,531 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 419 | 550 | $941,971 | $48,856 |
| 2022 | 8 | 461 | 640 | $666,818 | $55,556 |
| 2021 | 9 | 404 | 548 | $513,905 | $49,028 |
| 2020 | 9 | 407 | 501 | $589,872 | $41,237 |
Total Patients
1,691
Total Services
2,239
Medicare Billing
$194,676
Procedure Codes
36
All Medicare Procedures & Services
36 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 118 | 188 | $49,257 | $22,438 | 45.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 38 | 38 | $9,652 | $5,794 | 60.0% |
| 95911 | Nerve conduction, 9-10 studies | Facility | 2023 | 43 | 43 | $401,422 | $5,005 | 1.2% |
| 95912 | Nerve conduction, 11-12 studies | Facility | 2023 | 30 | 30 | $260,670 | $4,187 | 1.6% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Facility | 2023 | 66 | 81 | $23,281 | $3,289 | 14.1% |
| 95913 | Nerve conduction, 13 or more studies | Facility | 2023 | 17 | 17 | $164,466 | $2,921 | 1.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 16 | 16 | $12,112 | $2,559 | 21.1% |
| 95885 | Needle measurement of electrical activity in arm or leg muscles, limited study | Facility | 2023 | 61 | 98 | $10,932 | $1,673 | 15.3% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2023 | 30 | 39 | $10,179 | $990.92 | 9.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 149 | 250 | $94,838 | $29,688 | 31.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 62 | 62 | $31,498 | $10,171 | 32.3% |
| 95911 | Nerve conduction, 9-10 studies | Facility | 2022 | 42 | 42 | $333,804 | $4,781 | 1.4% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2022 | 70 | 110 | $28,710 | $3,054 | 10.6% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Facility | 2022 | 54 | 67 | $16,477 | $2,736 | 16.6% |
| 95912 | Nerve conduction, 11-12 studies | Facility | 2022 | 18 | 18 | $144,784 | $2,380 | 1.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 18 | 18 | $9,820 | $1,536 | 15.6% |
| 95885 | Needle measurement of electrical activity in arm or leg muscles, limited study | Facility | 2022 | 48 | 73 | $6,887 | $1,210 | 17.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 113 | 189 | $75,234 | $23,505 | 31.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 68 | 68 | $29,272 | $10,973 | 37.5% |
| 95911 | Nerve transmission studies, 9-10 studies | Facility | 2021 | 31 | 31 | $226,982 | $3,836 | 1.7% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2021 | 58 | 80 | $20,880 | $2,398 | 11.5% |
| 95912 | Nerve transmission studies, 11-12 studies | Facility | 2021 | 16 | 16 | $127,584 | $2,361 | 1.9% |
| 95886 | Needle measurement and recording of electrical activity of muscles of arm or leg complete study | Facility | 2021 | 46 | 54 | $12,744 | $2,192 | 17.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 21 | 23 | $11,576 | $1,747 | 15.1% |
| 95885 | Needle measurement and recording of electrical activity of muscles of arm or leg limited study | Facility | 2021 | 39 | 57 | $5,073 | $1,024 | 20.2% |
About Dr. Neelam Goyal, M.D
Dr. Neelam Goyal, M.D is a Electrodiagnostic Medicine healthcare provider based in Stanford, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/19/2009. The National Provider Identifier (NPI) number assigned to this provider is 1558500256.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Neelam Goyal, M.D has received a total of $179,087 in payments from pharmaceutical and medical device companies, with $78,898 received in 2024. These payments were reported across 172 transactions from 10 companies. The most common payment nature is "Consulting Fee" ($108,157).
As a Medicare-enrolled provider, Goyal has provided services to 1,691 Medicare beneficiaries, totaling 2,239 services with total Medicare billing of $194,676. Data is available for 4 years (2020–2023), covering 36 distinct procedure/service records.
Ad
Practice Information
- Specialty Electrodiagnostic Medicine
- Other Specialties Clinical Neurophysiology, Neurology
- Location Stanford, CA
- Active Since 02/19/2009
- Last Updated 11/10/2023
- Taxonomy Code 204R00000X
- Entity Type Individual
- NPI Number 1558500256
Products in Payments
- VYVGART (Drug) $29,322
- UPLIZNA (Biological) $12,597
- SOLIRIS (Biological) $10,897
- Zilbrysq (Drug) $10,515
- ULTOMIRIS (Biological) $6,541
- Hizentra (Biological) $5,177
- Rystiggo (Biological) $4,977
- Soliris (Drug) $1,020
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Electrodiagnostic Medicine Doctors in Stanford
Leslie Dorfman, Md, MD
Electrodiagnostic Medicine — Payments: $379.79
Electrodiagnostic Medicine $379.79
Sarada Sakamuri, Md, MD
Electrodiagnostic Medicine — Payments: $330.26
Electrodiagnostic Medicine $330.26
Joshua Levin, Md, MD
Electrodiagnostic Medicine — Payments: $302.72
Electrodiagnostic Medicine $302.72
Rebecca Miller-Kuhlmann, Md, MD
Electrodiagnostic Medicine
Electrodiagnostic Medicine